Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases
The purpose of this phase II study is to determine the impact of hepatic artery infusion (HAI) FUDR on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via a surgically placed HAI pump.
Study ID: 2017-349
Trial Phase: Phase II
Trial Sponsor: Spectrum Health Hospitals
Therapies Used in This Trial: Floxuridine